Clinical trials: Gastro Esophageal Reflux
Reflux Esophagitis
An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis
The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by…
- Trial name
- NCT01008696
- Testing
- Rabeprazole, Lansoprazole
- Volunteers
- 217 people
- Sponsor
- Janssen Korea, Ltd., Korea
Gastroesophageal Reflux Disease (GERD), Peptic Ulcers
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00261300
- Testing
- Pantoprazole
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Takeda
Reflux Oesophagitis
Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
The objective of the study was to assess whether the tolerance to the effect of YF476 on gastric pH observed with repeated doses in a previous study in healthy volunteers can be avoided by using smaller doses of YF476.
- Trial name
- NCT01597674
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
The study is designed to test the safety and efficacy of the Medigus SRS endoscopic stapling system for the treatment of GERD. The system allows the operator to staple the stomach to the esophagus,in order to restore the…
- Trial name
- NCT00734747
- Testing
- Medigus SRS endoscopic stapling system
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 72 people
- Sponsor
- Aviel Roy-Shapira, M.D.
Reflux Esophagitis (RE)
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
- Trial name
- NCT06850480
- Testing
- JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Reflux Esophagitis
The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient…
- Trial name
- X842 (NCT07079540)
- Testing
- X842, Lansoprazole
- Where
- 53 sites in China
- Volunteers
- 380 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastro Esophageal Reflux Disorder
Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers
A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult…
- Trial name
- NCT07727629
- Testing
- UI059, UIC202201
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00321737
- Testing
- Dexlansoprazole MR
- Where
- 98 sites in United States, Australia and 6 more
- Volunteers
- 445 people
- Sponsor
- Takeda
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.
- Trial name
- NCT03214952
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 3,183 people
- Sponsor
- Takeda
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving…
- Trial name
- NCT00660660
- Testing
- Esomeprazole
- Where
- 45 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Gastro Esophageal Reflux Disease
Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)
Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes.
- Trial name
- NCT01788085
- Testing
- Bravo pH monitoring procedure
- Where
- Israel
- Sponsor
- Medtronic - MITG
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Initial Treatment)
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by…
- Trial name
- NCT00633932
- Testing
- Esomeprazole, Omeprazole
- Where
- 41 sites in Japan
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
The purpose of this survey is to evaluate the safety and effectiveness of long-term administration of vonoprazan tablets when used as maintenance therapy for reflux esophagitis in routine clinical settings.
- Trial name
- NCT03214081
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 1,237 people
- Sponsor
- Takeda
GERD, Gastroesophageal Reflux
Observational Study of Anti-Reflux Surgery
The Anti-Reflux Surgical Study has been established to: Collect data about anti-reflux surgical treatment options (magnetic sphincter augmentation and Fundoplication) in everyday clinical practice Track the clinical course of…
- Conditions
- GERD, Gastroesophageal Reflux, Gastro Esophageal Reflux
- Trial name
- NCT01624506
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 760 people
- Sponsor
- Torax Medical Incorporated
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily [QD]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
- Trial name
- NCT05195528
- Testing
- Vonoprazan
- Where
- 108 sites in United States
- Volunteers
- 776 people
- Sponsor
- Phathom Pharmaceuticals, Inc.